This project has two purposes. As the statistics and bioinformatics core, the project will provide statistical and database support to other superfund projects. This will typically involve assistance in experimental design, in the analysis and interpretation of data, in the proposal and development of appropriate statistical methods of data analysis, and in the storage and analysis of microarray, mass spectrometry, and NMR spectroscopy data. In addition, this project proposes the development and refinement of statistical methods and algorithms for the analysis of toxics measurement data, gene expression data, proteomics data, and for the creation of new and improved measurement techniques. A particular emphasis is on the development of new statistical methods for design and analysis of experiments using microarrays (including immunoarrays, DNA arrays, and oligonucleotide arrays), mass spectrometry, and NMR spectroscopy, as well as assisting with the bioinformatics needs associated with these data-intensive methods. We will help deal with such problems as background and baseline correction, peak alignment, compound identification, nonlinear calibration, nonconstant variance, outliers, values near or below detection limits, and high-dimensional and large data sets. Many analytical methods can be made more efficient and effective by careful statistical design and analysis of the data. This may be important to human health, since it allows more frequent monitoring of hazardous sites or for human biomarkers of exposure for the same cost, and since it aids in the development and use of analytical techniques to detect toxic substances both clinically and in the field at lower levels and with greater accuracy than existing methods.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-22
Application #
7597033
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
22
Fiscal Year
2008
Total Cost
$67,050
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications